Schering Looking To Expand Therapeutic Frontiers Beyond Cholesterol
Executive Summary
Schering-Plough is positioning itself to branch out from its cholesterol base into other therapeutic areas, CEO Fred Hassan said at the Morgan Stanley CEOs Unplugged investor conference on Jan. 4
You may also be interested in...
Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition
Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking
Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition
Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking
Schering-Plough To Hone Its Edge In “Build The Base” Phase
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20